|Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer|
EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ...
New England Journal of Medicine 363 (18), 1693-1703, 2010
|ROS1 rearrangements define a unique molecular class of lung cancers|
K Bergethon, AT Shaw, SHI Ou, R Katayama, CM Lovly, NT McDonald, ...
Journal of clinical oncology 30 (8), 863, 2012
|Crizotinib in ROS1-rearranged non–small-cell lung cancer|
AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, ...
New England Journal of Medicine 371 (21), 1963-1971, 2014
|Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study|
DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ...
The lancet oncology 13 (10), 1011-1019, 2012
|Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer|
S Peters, DR Camidge, AT Shaw, S Gadgeel, JS Ahn, DW Kim, SHI Ou, ...
New England Journal of Medicine 377 (9), 829-838, 2017
|Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis|
AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ...
The lancet oncology 12 (11), 1004-1012, 2011
|Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs|
SH Ou, F Wu, D Harrich, LF García-Martínez, RB Gaynor
Journal of virology 69 (6), 3584-3596, 1995
|Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG …|
SM Gadgeel, L Gandhi, GJ Riely, AA Chiappori, HL West, MC Azada, ...
The Lancet Oncology 15 (10), 1119-1128, 2014
|Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study|
SHI Ou, JS Ahn, L De Petris, R Govindan, JCH Yang, B Hughes, H Lena, ...
Journal of clinical oncology 34 (7), 661-668, 2016
|Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3 …|
JCH Yang, LV Sequist, SL Geater, CM Tsai, TSK Mok, M Schuler, ...
The lancet oncology 16 (7), 830-838, 2015
|Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial|
AT Shaw, L Gandhi, S Gadgeel, GJ Riely, J Cetnar, H West, DR Camidge, ...
The lancet oncology 17 (2), 234-242, 2016
|Clinical experience with crizotinib in patients with advanced ALK-rearranged non–small-cell lung cancer and brain metastases|
DB Costa, AT Shaw, SHI Ou, BJ Solomon, GJ Riely, MJ Ahn, C Zhou, ...
Journal of Clinical Oncology 33 (17), 1881, 2015
|STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma|
F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ...
Cancer discovery 8 (7), 822-835, 2018
|Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors|
GM Frampton, SM Ali, M Rosenzweig, J Chmielecki, X Lu, TM Bauer, ...
Cancer discovery 5 (8), 850-859, 2015
|ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non–small cell lung cancer|
JF Gainor, AM Varghese, SHI Ou, S Kabraji, MM Awad, R Katayama, ...
Clinical cancer research 19 (15), 4273-4281, 2013
|Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)|
A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Cancer discovery 7 (4), 400-409, 2017
|Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial|
JCH Yang, JY Shih, WC Su, TC Hsia, CM Tsai, SHI Ou, CJ Yu, GC Chang, ...
The lancet oncology 13 (5), 539-548, 2012
|Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with …|
SHI Ou, EL Kwak, C Siwak-Tapp, J Dy, K Bergethon, JW Clark, ...
Journal of thoracic oncology 6 (5), 942-946, 2011
|Elevation of hepatic glutathione S-transferase activities and protection against mutagenic metabolites of benzo (a) pyrene by dietary antioxidants|
AM Benson, RP Batzinger, SYL Ou, E Bueding, YN Cha, P Talalay
Cancer Research 38 (12), 4486-4495, 1978
|Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study|
BJ Solomon, B Besse, TM Bauer, E Felip, RA Soo, DR Camidge, R Chiari, ...
The Lancet Oncology 19 (12), 1654-1667, 2018